BioMed Research International / 2022 / Article / Tab 1 / Research Article
The Evaluation of the Efficacy and Safety of Oral Colchicine in the Treatment of Knee Osteoarthritis: A Meta-Analysis of Randomized Controlled Trails Table 1 Basic characteristics of included studies.
Author; year LEO at baselineFemale (%) Grade of OA Dose Primary outcome measures Adverse events ( ) Follow-up (month) Amirpour et al. 2016 [20 ] I 81 98 Not mentioned 0.5 mg/bid VAS; modified WOMAC index C: 2; P: 5 4 Aran et al. 2011 [19 ] I 61 100 Primary OA 0.5 mg/bid Patients’ global assessment; physician’s global assessment (recorded on VAS) C: 1; P: 0 3 Das et al. 2002‡ [18 ] I 36 77.8 Moderately severe symptomatic OA 0.5 mg/bid Index knee pain (VAS); total WOMAC scores. C: 11; P: 4 5 Das et al. 2002† [12 ] I 39 66.7 Not mentioned 0.5 mg/bid Vas pain; Total KGMC scale (modified WOMAC index suit for India) C: 33; P: 47 5 Leung et al. 2018 [21 ] I 109 70.7 0-IV (KL grade) 0.5 mg/bid Total WOMAC score; improvement in pain (VAs); C: 95; P: 67 4
LOE: level of evidence;
: number; SD: standard deviation; NA: not applicable; OA: osteoarthritis; KL: Kellgren and Lawrence grading system; WOMAC: Western Ontario and McMaster University Osteoarthritis Index; VAS: visual analog scale; C: colchicine group; P: placebo group.